Researchers from The University of Texas MD Anderson Cancer Center found that patients with specific mutations in the STK11 and/or KEAP1 genes with metastatic non-squamous non-small cell lung cancer may benefit from adding the immunotherapy tremelimumab to durvalumab plus chemotherapy. Results published in Nature suggest these mutations could be used as biomarkers to identify patients who would benefit from dual immune checkpoint inhibition. Patients with these mutations showed better outcomes with the combination treatment compared to standard therapies. Preclinical models further supported the use of dual checkpoint inhibitors for these patients. Future trials will explore this treatment approach in a larger patient population.
Source link
Dual immunotherapy plus chemotherapy shows promise for specific lung cancer patients
